Acarix
0.246 SEK +0.2%Be the first to follow this company
Acarix is a diagnostics company. The company has developed a technology that enables the identification of coronary heart disease. The company's product is a non-invasive test that is put with a note on the patient to analyze sound from the heart. Operations are mainly conducted in the Nordic market. The company was founded in 2009 as a spin-off from Coloplast. The head office is located in Malmö.
Revenue
6.24M
EBIT %
-1,242.79 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
ACARIX
Daily low / high price
0.239 / 0.254
SEK
Market cap
225.42M SEK
Turnover
484.02K SEK
Volume
2M
Financial calendar
General meeting
2024-05-14
Interim report
2024-05-14
Interim report
2024-08-22
Interim report
2024-11-07
Annual report
2025-02-13
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Försäkringsaktiebolaget, Avanza Pension | 8.4 % | 8.4 % |
Mikael Thorén | 4.2 % | 4.2 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
NOTICE OF ANNUAL GENERAL MEETING IN ACARIX AB
Acarix announces the initiation of the first US-based clinical workflow evaluation study
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools